PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsGilvetmab
Gilvetmab
Gilvetmab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
3878 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MelanomaD00854520233139
Non-small-cell lung carcinomaD0022891424330
NeoplasmsD009369C8026171130
Neoplasm metastasisD009362EFO_000970886113
Squamous cell carcinoma of head and neckD00007719558112
Renal cell carcinomaD002292EFO_000037687112
Lung neoplasmsD008175C34.9058111
Breast neoplasmsD001943EFO_0003869C504618
Head and neck neoplasmsD0062584417
Brain neoplasmsD001932EFO_0003833C712417
Show 6 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pancreatic neoplasmsD010190EFO_0003860C25101014
Colorectal neoplasmsD0151799812
GlioblastomaD005909EFO_0000515627
Colonic neoplasmsD003110C18356
Cutaneous malignant melanomaD000096142336
AdenocarcinomaD000230245
Prostatic neoplasmsD011471C61255
GliomaD005910EFO_0000520335
Transitional cell carcinomaD002295525
Liver neoplasmsD008113EFO_1001513C22.0445
Show 65 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749C6733
Glandular and epithelial neoplasmsD00937522
MyoepitheliomaD00920822
Hepatitis cD006526B19.211
HepatitisD006505K75.911
Hepatitis aD006506EFO_0007305B1511
Multiple myelomaD009101C90.011
Neoplasms by histologic typeD00937011
Urinary bladder diseasesD001745N32.911
AstrocytomaD001254EFO_000027111
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGilvetmab
INNgilvetmab
Description
Gilvetmab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL3990007
ChEBI ID
PubChem CID
DrugBank
UNII ID949NG8376D (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 60,664 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
25 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use